Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients

Fudan University

Status: Completed

Conditions: Hepatocellular Cancer (HCC)

Treatments: Procedure: TACE; Drug: compound mylabris capsule; Drug: Thalidomide (50mg); Drug: carmofur

Study type: Observational

Funder types: Other

Identifiers

NCT07321613

20251111101713560

Details and patient eligibility

About

This is a multicenter, retrospective cohort study that aims to evaluate the efficacy and safety of a triple-drug cocktail (TCC), consisting of Thalidomide, Carmofur, and Compound Mylabris Capsules (CMC), in combination with conventional Transarterial Chemoembolization (TACE) for the treatment of patients with unresectable Hepatocellular Carcinoma (HCC).

Enrollment: 545 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients who met the HCC diagnostic criteria according to the Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China.
• patients underwent conventional TACE.
• availability of complete medical records for data extraction and follow-up.

Exclusion criteria

• a history of previous or synchronous treatment for tumors such as radio frequency ablation (RFA) or systemic chemotherapy.
• poor liver functions (Child-Pugh class C).
• accompanying other life-threatening diseases.

Trial design

545 participants in 2 patient groups

TACE+cocktail

Description:

Patients in the TACE+cocktail group received TACE and took the combined oral medications daily, which consisted of thalidomide tablets, carmofur tablets , and compound mylabris capsule.

Treatment:

Drug: carmofur

Drug: Thalidomide (50mg)

Drug: compound mylabris capsule

Procedure: TACE

TACE only

Description:

Patients in the TACE only group received only TACE treatment.

Treatment:

Procedure: TACE